Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.

Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.
复制标题

DOI:
10.3390/cells10050968
复制
发表时间:
2021-04-21
期刊:
影响因子:
6
通讯作者:
Flores CT
Flores CT
中科院分区:
生物学2区
文献类型:
--
作者:
Wildes TJ;DiVita Dean B;Flores CT

文献摘要

参考文献

被引文献

相似文献

我们对免疫系统和癌症之间关系的理解最近有了重大发现。T细胞疗法和检查点阻断的免疫疗法已经有意义地改变了肿瘤学格局。虽然适应性免疫的临床进展显著,但先天免疫的调节已被证明更为困难。髓样区室,包括巨噬细胞、中性粒细胞和树突状细胞,对肿瘤的持续存在或消除具有显著影响。骨髓细胞,特别是在肿瘤微环境中,与肿瘤组织直接接触,并与肿瘤反应性T细胞协调,以刺激或拮抗癌症免疫。然而,髓样区室包括处于不同发育阶段的广泛的细胞阵列。此外,在骨髓生成的不同阶段,远端部位的造血干细胞和祖细胞受到肿瘤的显著调节。了解肿瘤如何对髓系祖细胞产生影响,对于在这些途径中进行有临床意义的改善至关重要。因此,这篇综述将涵盖我们对实体瘤如何调节骨髓生成以促进促肿瘤未成熟髓系细胞形成的理解的最新进展。然后,它将涵盖利用这些机制产生抗肿瘤免疫的一些潜在途径。
Our understanding of the relationship between the immune system and cancers has undergone significant discovery recently. Immunotherapy with T cell therapies and checkpoint blockade has meaningfully changed the oncology landscape. While remarkable clinical advances in adaptive immunity are occurring, modulation of innate immunity has proven more difficult. The myeloid compartment, including macrophages, neutrophils, and dendritic cells, has a significant impact on the persistence or elimination of tumors. Myeloid cells, specifically in the tumor microenvironment, have direct contact with tumor tissue and coordinate with tumor-reactive T cells to either stimulate or antagonize cancer immunity. However, the myeloid compartment comprises a broad array of cells in various stages of development. In addition, hematopoietic stem and progenitor cells at various stages of myelopoiesis in distant sites undergo significant modulation by tumors. Understanding how tumors exert their influence on myeloid progenitors is critical to making clinically meaningful improvements in these pathways. Therefore, this review will cover recent developments in our understanding of how solid tumors modulate myelopoiesis to promote the formation of pro-tumor immature myeloid cells. Then, it will cover some of the potential avenues for capitalizing on these mechanisms to generate antitumor immunity.
DOI: 10.4049/jimmunol.166.1.678
发表时间: 2001-01-01
影响因子: 4.4
作者:
Almand, B;Clark, JI;Gabrilovich, DI
通讯作者: Gabrilovich, DI
DOI: 10.1006/cimm.1996.0140
发表时间: 1996-05-25
影响因子: 4.3
作者:
Gabrilovich, DI;Nadaf, S;Carbone, DP
通讯作者: Carbone, DP
DOI: 10.1073/pnas.1113744109
发表时间: 2012-02-14
影响因子: 11.1
作者:
Cortez-Retamozo, Virna;Etzrodt, Martin;Pittet, Mikael J.
通讯作者: Pittet, Mikael J.
DOI: 10.7759/cureus.12899
发表时间: 2021-01-25
期刊: Cureus
影响因子: --
作者:
De Leo EK;Shah CP;Grajo JR;Liu X;Parekh H
通讯作者: Parekh H
DOI: 10.1186/s40425-017-0257-y
发表时间: 2017-07-18
影响因子: 10.9
作者:
Cannarile MA;Weisser M;Jacob W;Jegg AM;Ries CH;Rüttinger D
通讯作者: Rüttinger D